Abstract
Advanced chronic kidney disease (CKD) results in a constellation of dysregulation of lipid metabolism, oxidative stress, and inflammation which are causally interconnected and participate in a vicious cycle. The CKD-associated lipid disorders are marked by impaired clearance of very low density lipoprotein and chylomicrons, hypertriglyceridemia, formation of small dense low-density lipoprotein (LDL), oxidative modification of LDL, intermediate density lipoprotein and chylomicron remnants, and high-density lipoprotein deficiency and dysfunction. This review provides a brief overview of the role of CKD-induced lipid disorders in the pathogenesis of oxidative stress, inflammation, cardiovascular disease, impaired exercise capacity, cachexia and wasting syndrome.
Similar content being viewed by others
References
Vaziri ND, Norris K. Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif. 2011;31:189–96.
Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms and potential consequences. Am J Physiol, Renal Physiol. 2006;290:262–72.
Vaziri ND, Moradi H. Mechanism of dyslipidemia of chronic renal failure. Hemodial Int. 2006;10:1–7.
Kaysen GA. New insights into lipid metabolism in chronic kidney disease. J Ren Nutr. 2011;21(1):120–3.
Rajman I, Harper L, McPake D, et al. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant. 1998;13:2281–7.
Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:852–62.
Kronenberg F, Neyer U, Lhotta K, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999;10:1027–36.
Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6(5):287–96.
Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int. 1990;37:854–8.
Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1928–35.
Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol. 1997;273:F925–30.
Vaziri ND, Yuan J, Ni Z, Nicholas SB, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is compounded by downregulation of endothelial GPIHBP1 expression. Clin Exp Nephrol. 2012;16:238–43.
Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 2001;108:779–84.
Kim C, Vaziri ND. Downregulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int. 2005;67:1028–32.
Pahl MV, Ni Z, Sepassi L, Vaziri ND. Plasma phospholipid transfer protein, cholesterol ester transfer protein and lecithin: cholesterol acyltransferase in end-stage renal disease. Nephrol Dial Transplant. 2009;24(8):2541–6.
Klin M, Smogorzewski M, Ni Z, Zhang G, Massry SG. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest. 1996;97:2167–73.
Liang K, Vaziri ND. Downregulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int. 1997;51:1933–7.
Sato T, Liang K, Vaziri ND. Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor deficiencies in focal glomerulosclerosis. Kidney Int. 2003;64:1780–6.
Takahashi S, Kawarabayasi Y, Nakai T, et al. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA. 1992;89:9252–6.
Liang K, Vaziri ND. Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int. 1997;51:1761–5.
Sato T, Liang K. VaziriND: downregulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int. 2002;61:157–62.
Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol (2012) pii: S0735-1097(12)04651-7.
Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int. 2009;76(4):437–44.
Moradi H, Said HM, Vaziri ND Post-transcriptional nature of uremia-induced down-regulation of hepatic apolipoprotein A-I production. Transl Res PMID: 23219399, (2012).
Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein. Curr Opin Cardiol. 2006;21:322–8.
Liang K, Vaziri ND. Upregulation of Acyl-CoA: cholesterol acyltransferase (ACAT) in chronic renal failure. Am J Physiol Endocrinol Metab. 2002;283:E676–81.
Kim HJ, Moradi H, Vaziri ND. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol. 2009;296(6):F1297–306.
Moradi H, Yuan J, Ni Z, Norris K, Vaziri ND. Reverse cholesterol transport pathway in experimental chronic kidney disease. Am J Nephrol. 2009;30:147–54.
Vaziri ND, Bai Y, Yuan J, Said H, Sigala W, Ni Z. ApoA-1 mimetic peptide reverses uremia-induced up-regulation of pro-atherogenic pathways in the aorta. Am J Nephrol. 2010;32(3):201–11.
Vaziri ND, Liang K, Parks JS. Downregulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192–6.
Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezón E, Champagne E, Pineau T, Georgeaud V, Walker JE, Tercé F, Collet X, Perret B, Barbaras R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature. 2003;421:75–9.
Adams G, Vaziri ND. Skeletal muscle dysfunction in chronic renal failure: effect of exercise. Am J Physiol Renal Physiol. 2006;290:783–91.
Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503–16.
Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation. 2000;101:2889–95.
Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.
Collins AJ, Foley R, Herzog C, et al. Excerpts from the US renal data system 2007 annual data report. Am J Kidney Dis. 2008;51:S1–320.
Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004;15(Suppl. 1):S77–80.
Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol. 2010;6:723–35.
Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant. 2000;15(2):218–23.
Pecoits-Filho R, Lindholm B, Stenvinkel P. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome––the heart of the matter. Nephrol Dial Transplant. 2002;17(Suppl 11):28–31.
Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451–9.
Kilpatrick RD, McAllister CJ, Kovesdy CP, et al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293–303.
Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.
Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.
Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomized placebo-controlled trial. Lancet. 2011;377:2181–92.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Vaziri, N.D. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease . Clin Exp Nephrol 18, 265–268 (2014). https://doi.org/10.1007/s10157-013-0847-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-013-0847-z